How do you hurt us? Let me count the ways: Assobiotec's Palmisano's lament
This article was originally published in Scrip
Executive Summary
Italy is preparing to sign off swingeing new measures to contain drug spending as part of a broad Spending Review, while its Health Ministry is calling for measures that could allow unapproved medicines access to the market if they offer a significant discount to medicines on the market for the same indication (scripintelligence.com, 26 July 2012). Riccardo Palmisano, executive vice-president of the biotechnology association Assobiotec, talked to Scrip's Eleanor Malone about the threats to industry and his fears and frustrations in this regard.